-
![Nicolas Poirier_OSE Immunotherapeutics]( "Companies To Watch: OSE Immunotherapeutics")
Companies To Watch: OSE Immunotherapeutics4/22/2024OSE Immunotherapeutics is poised to begin a confirmatory and pivotal Phase 3 trial for a novel cancer vaccine targeting the second line in NSCLC, an area of acute unmet need.
-
![Yaacov Michlin]( "A View From The Co-Chair Of Israel’s Biopharma Industry Trade Organization")
A View From The Co-Chair Of Israel’s Biopharma Industry Trade Organization3/28/2024Yaacov Michlin, co-chair of the IATI, discusses the advantages and disadvantages of Israel’s biopharma industry, the industry impact of the war in Gaza, and the difference between the U.S. and Israel regarding Chinese CDMOs.
-
![John Valliant_Fusion Pharma]( "Why Fusion Pharma Is The Latest Billion Dollar Big Pharma Buy In Radiopharmaceuticals")
Why Fusion Pharma Is The Latest Billion Dollar Big Pharma Buy In Radiopharmaceuticals3/22/2024AstraZeneca's $2.4 billion acquisition of Fusion Pharma is the third billion dollar radiopharmaceuticals deal in recent months. John Valliant, Fusion's founder and CEO, explains why alpha-emitters are better than beta-emitters, and why radiopharmaceuticals are poised for substantial growth.
-
![WATN_Novo Nordisk]( "Where Are They Now? Novo Nordisk")
Where Are They Now? Novo Nordisk3/18/2024In a few short years, Novo Nordisk has gone from belt-tightening to parachute pants, and is now replaying a GLP-1 competition with Eli Lilly that kicked off with Victoza and Trulicity ten years ago.
-
![Sam Clark_Terran Biosciences (002)]( "A Proactive Approach To ‘Unscrupulous’ Patent Practices")
A Proactive Approach To ‘Unscrupulous’ Patent Practices3/7/2024Terran Biosciences aims to subvert a patent strategy some drugmakers have used to delay the entrance of generic competitors. The company is patenting its own psychedelic salts, polymorphs, and prodrugs, and targeting FDA's 505(b)(2) pathway.
-
![Rare Disease Day_Image 1367968418]( "NORD Expands Advocacy And Support For Rare Disease Patients, And Industry")
NORD Expands Advocacy And Support For Rare Disease Patients, And Industry2/29/2024NORD's president and CEO, Peter Saltonstall, offers details on the organization's current activities and ongoing work with biopharmaceutical companies developing rare disease drugs.
-
![Ben Comer_450x300]( "The Good And Bad Of Copromotion")
The Good And Bad Of Copromotion2/26/2024Are two minds, or companies, better than one for drug commercialization? It depends on the details, says Eisai's Paul Hawthorne.
-
![PAUL_HAWTHORNE]( "No Playbook For Leqembi: Eisai’s Long Game In Alzheimer’s Disease")
No Playbook For Leqembi: Eisai’s Long Game In Alzheimer’s Disease2/16/2024Paul Hawthorne, Eisai's EVP, purpose and chief business officer, offers insight into building a market for Leqembi, Eisai's pricing and commercial strategy, and the challenges and opportunities in Alzheimer's disease.
-
![DYNAVAX_Superweek_001]( "Dynavax’s Evolving Business Model")
Dynavax’s Evolving Business Model2/9/2024Dynavax found a new revenue stream during COVID, and a way to grow market share in the absence of a market. Ryan Spencer describes the ups and downs, and his own journey to CEO role.
Ben Comer
Ben Comer is chief editor of Life Science Leader magazine. He has covered the biopharmaceutical, medtech and medical device industries for 15 years as a reporter and editor, and worked as a senior manager in PwC’s Health Research Institute. Comer was most recently executive editor at In Vivo magazine, where he wrote feature stories, executive profiles and articles ranging from pre-clinical biotech strategy, fundraising, supply chain, manufacturing, and regulatory issues, to global commercialization efforts, market access and environmental, social and governance topics. He has interviewed hundreds of executives and experts at biopharmaceutical and life science companies, academic institutions, law firms, patient advocacy groups, payer and provider organizations, industry trade associations and regulatory bodies. Comer has presented and moderated panels at dozens of industry conferences, convened webcasts with industry leaders, and published news articles and other writing in Scrip, Pink Sheet, MedTech Insight, Generics Bulletin, Pharmaceutical Executive, PharmTech, Applied Clinical Trials, Medical Marketing & Media and PR Week, among others. Comer is a graduate of the College of Charleston and has worked in compounding pharmacies as a certified technician. You can find him on Twitter @BenMComer.